Pemgarda is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to Pemgarda is less than or equal to 90%.

The intervention was completed by 108 participants. The researchers found that TRE improved HbA1c by −0.10% compared with SOC.

Researchers assessed the safety, efficacy, and tolerability of various doses of zasocitinib among patients with moderate to severe plaque psoriasis.

Overall, 255,789 patients made 953,402 primary care visits during UC and 228,255 patients made 615,511 visits during SC.

In the TEMPO-1 trial, participants with early PD were randomly assigned to receive tavapadon 5mg or 15mg once daily or placebo.

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.